Exploring Targeted Therapy for T-Cell Lymphoma After CAR T-Cell Therapy

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.

Samir Parekh, MD, discusses managing a rare T-cell lymphoma post BCMA CAR T-cell therapy and how CCR4-targeted treatment achieved durable remission.